130 related articles for article (PubMed ID: 38884946)
1. The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
Lai S; Luo S; Huang Q; Lin S; Huang X; Xue H; Cai Y; Xu X; Weng X
Pharmacogenomics; 2024 May; ():1-9. PubMed ID: 38884946
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.
Huang Y; You M; Wu Q; Chen R
Front Pharmacol; 2023; 14():1238009. PubMed ID: 37719841
[No Abstract] [Full Text] [Related]
3. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA; Shitara K; Ajani JA; Bang YJ; Enzinger P; Ilson D; Lordick F; Van Cutsem E; Gallego Plazas J; Huang J; Shen L; Oh SC; Sunpaweravong P; Soo Hoo HF; Turk HM; Oh M; Park JW; Moran D; Bhattacharya P; Arozullah A; Xu RH
Nat Med; 2023 Aug; 29(8):2133-2141. PubMed ID: 37524953
[TBL] [Abstract][Full Text] [Related]
4. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
5. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.
Sahin U; Türeci Ö; Manikhas G; Lordick F; Rusyn A; Vynnychenko I; Dudov A; Bazin I; Bondarenko I; Melichar B; Dhaene K; Wiechen K; Huber C; Maurus D; Arozullah A; Park JW; Schuler M; Al-Batran SE
Ann Oncol; 2021 May; 32(5):609-619. PubMed ID: 33610734
[TBL] [Abstract][Full Text] [Related]
6. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Cutsem EV; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
Future Oncol; 2024 May; ():1-17. PubMed ID: 38861294
[TBL] [Abstract][Full Text] [Related]
7. Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
Nishibata T; Weng J; Omori K; Sato Y; Nakazawa T; Suzuki T; Yamada T; Nakajo I; Kinugasa F; Türeci Ö; Şahin U; Yoshida T
J Pharmacol Sci; 2024 Jul; 155(3):84-93. PubMed ID: 38797537
[TBL] [Abstract][Full Text] [Related]
8. ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ; Lee KW; Shitara K; Metges JP; Lonardi S; Ilson DH; Fazio N; Kim TY; Bai LY; Moran D; Yang J; Arozullah A; Park JW; Raizer JJ; Bang YJ; Shah MA
Clin Cancer Res; 2023 Oct; 29(19):3882-3891. PubMed ID: 37490286
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
de Moraes FCA; Pasqualotto E; Chavez MP; Ferreira ROM; De Castria TB; Burbano RMR
BMC Cancer; 2024 Feb; 24(1):240. PubMed ID: 38383390
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Morimoto K; Moriwaki K; Shimozuma K; Nakayama T
J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256
[TBL] [Abstract][Full Text] [Related]
11. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis.
Zhang PF; Shi XQ; Li Q
Cost Eff Resour Alloc; 2023 Sep; 21(1):65. PubMed ID: 37705023
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O; Sahin U; Schulze-Bergkamen H; Zvirbule Z; Lordick F; Koeberle D; Thuss-Patience P; Ettrich T; Arnold D; Bassermann F; Al-Batran SE; Wiechen K; Dhaene K; Maurus D; Gold M; Huber C; Krivoshik A; Arozullah A; Park JW; Schuler M
Ann Oncol; 2019 Sep; 30(9):1487-1495. PubMed ID: 31240302
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
Shu Y; Ding Y; Zhang Q
Front Oncol; 2022; 12():851522. PubMed ID: 35515123
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tislelizumab plus chemotherapy vs chemotherapy as first-line treatment of PD-L1 positive advanced gastric or gastroesophageal junction adenocarcinoma from a Chinese perspective.
Li W; Wan L; Zhang J
Expert Rev Gastroenterol Hepatol; 2024 Jun; ():1-9. PubMed ID: 38923910
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials.
Liang Z; Liu L; Li W; Lai H; Li L; Wu J; Zhang H; Fang C
Front Oncol; 2023; 13():1258347. PubMed ID: 37886169
[TBL] [Abstract][Full Text] [Related]
17. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context.
Wu B; Ye M; Chen H; Shen JF
Clin Ther; 2012 Feb; 34(2):468-79. PubMed ID: 22325735
[TBL] [Abstract][Full Text] [Related]
18. First-line nivolumab plus chemotherapy
Cao X; Zhang M; Li N; Zheng B; Liu M; Song X; Cai H
Ther Adv Med Oncol; 2023; 15():17588359231171038. PubMed ID: 37223263
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Jiang Y; Li Y; Wang LXW
Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
Peng J; Tan C; Zeng X; Liu S
PLoS One; 2018; 13(6):e0199553. PubMed ID: 29953476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]